Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02414230 · ClinicalTrials.gov registry record
F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis
A clinical trial, sponsored by Tammie L. S. Benzinger, MD, PhD.
- Completed
- Registry status
- 9
- Enrollment target
NCT02414230 is a clinical trial that has completed, run by Tammie L. S. Benzinger, MD, PhD. The registered enrollment target is 9 participants.
The verdict
NCT02414230 has completed, sponsored by Tammie L. S. Benzinger, MD, PhD.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate tau distribution in the brain of subjects with: ALS caused by different genetic mutations, any mutation carriers (with or without symptoms), any non-mutation carrier, any sporadic FTD, normal controls.
Interventions
- DRUG Drug: F 18 T807
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-02 |
| Est. Completion | 2020-06-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02414230
The ClinicalTrials.gov registry entry for NCT02414230 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tammie L. S. Benzinger, MD, PhD, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drug: F 18 T807 is the first listed.
NCT02414230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02414230 about?
NCT02414230 is a clinical study titled "F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis". The purpose of this research study is to evaluate tau distribution in the brain of subjects with: ALS caused by different genetic mutations, any mutation carriers (with or without symptoms), any non-mutation carrier, any sporadic FTD, normal controls.
What is the current status of trial NCT02414230?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2015-02. Estimated completion is 2020-06-10.
What interventions are being tested in trial NCT02414230?
The interventions under investigation include: Drug: F 18 T807 (DRUG).
Who is sponsoring clinical trial NCT02414230?
This trial is sponsored by Tammie L. S. Benzinger, MD, PhD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.